WallStSmart
RPRX

Royalty Pharma Plc

NASDAQ: RPRX · HEALTHCARE · BIOTECHNOLOGY

$49.49
-0.10% today

Updated 2026-04-29

Market cap
$29.37B
P/E ratio
27.83
P/S ratio
12.35x
EPS (TTM)
$1.78
Dividend yield
1.77%
52W range
$31 – $50
Volume
3.2M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Royalty Pharma Plc (RPRX) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$49.49
Consensus
$47.75
-3.52%
2030 Target
—
—
DCF
$39.62
-11.69% MoS
4 analysts:
1 Buy2 Hold0 Sell

Management guidance

Royalty Pharma provided FY2026 guidance projecting 5.5% receipt growth midpoint from 2025 baseline of $2.38B, implying ~$2.51B in 2026 receipts. Management emphasized portfolio expansion through $2.6B in deployed capital in 2025 and four new royalty transactions valued up to $4.7B, positioning for accelerating growth in outer years as these assets mature.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$102.00
—
Base case (2030)
$63.14
—
Bear case (2030)
$43.71
—

Financial forecast — research-backed

Metric2023202420252026 (E)2028 (E)2029 (E)
Revenue$2.4B$2.3B$2.4B$2.5B$2.8B$3.0B
Revenue growth—-3.9%5.1%5.5%6.4%7.1%
EPS$4.75$3.21$4.84$5.17$5.95$6.42
P/S ratio———12.0x12.0x12.0x
Implied price———$53.43$58.28$63.14

Catalysts & risks

Growth catalysts
+ Portfolio expansion: $4.7B in new royalty transactions announced in Q4 2025 (Teva vitiligo, Denali $275M, Zymeworks $250M, Nuvalent $315M, Roche Evrysdi $240M) driving revenue growth 2026-2030
+ Pivotal study results on development-stage candidates (20+ in portfolio) expected to unlock value and increase royalty receipts
+ Strategic acquisitions of remaining royalty interests (Evrysdi acquisition completed Dec 2025) consolidating control and enhancing economics
+ AI integration and expanded Asia operations under new leadership signaling operational leverage and geographic diversification
+ Dividend increases for 6 consecutive years and $1.2B share buyback in 2025 demonstrating capital return confidence
Key risks
- Portfolio concentration risk: revenue dependent on performance of core royalty products; clinical/commercial failures could materially impact receipts
- Regulatory and pricing pressure on pharmaceutical products underlying royalty streams, particularly in US and EU markets
- Interest rate sensitivity: company carries $8.95B total debt; rising rates increase financing costs and reduce NPV of royalty valuations
- Integration execution risk on $2.6B+ annual deployment; identifying and acquiring accretive royalties at disciplined prices
- Insider selling activity (CFO Coyne, EVP Marshall) suggests management may view current valuation as rich despite bullish guidance

Methodology

Royalty Pharma Plc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 4 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.